2023
Rekindling Joy in Medicine Through Thoughtful Communication: A Practical Guide.
Sanft T, Winer E. Rekindling Joy in Medicine Through Thoughtful Communication: A Practical Guide. American Society Of Clinical Oncology Educational Book 2023, 43: e100034. PMID: 37267275, DOI: 10.1200/edbk_100034.Peer-Reviewed Original Research
2019
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.
Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precision Oncology 2019, 3: 1-9. PMID: 32923853, PMCID: PMC7446367, DOI: 10.1200/po.19.00087.Peer-Reviewed Original ResearchMetastatic breast cancerEligible patientsBreast cancerExact testHER2-negative breast cancerOngoing phase II trialGenomic profilingPhase II trialProportion of patientsComprehensive genomic profilingRoutine clinical practiceFisher's exact testGenomic tumor profilingArchived tissue samplesII trialMedian timeTRIAL REGISTRATIONTrial participationClinical trialsSpecific genomic changesClinical impactGenomic testing resultsRare subsetPatientsClinical practice
2015
Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women
Collins LC, Gelber S, Marotti JD, White S, Ruddy K, Brachtel EF, Schapira L, Come SE, Borges VF, Schedin P, Warner E, Wensley T, Tamimi RM, Winer EP, Partridge AH. Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. The Oncologist 2015, 20: 713-718. PMID: 26025931, PMCID: PMC4492229, DOI: 10.1634/theoncologist.2014-0412.Peer-Reviewed Original ResearchConceptsBreast cancer molecular phenotypesBreast cancerYoung womenFamily historyPregnancy-associated breast cancerMolecular phenotypesTumor histologic gradeBreast cancer riskBreast cancer phenotypeLast pregnancyParous womenProspective cohortCentral reviewHistologic gradeLike subtypeMolecular subtypesLarge cohortCancer riskPregnancyClinical practiceStudy questionnaireBiomarker expressionCancerTumor phenotypeWomen
2014
Adjuvant Chemotherapy in Breast Cancer
Lim E, Goel S, Winer E. Adjuvant Chemotherapy in Breast Cancer. 2014, 335-351. DOI: 10.1007/978-1-4939-1145-5_23.Peer-Reviewed Original ResearchAdjuvant chemotherapyAdjuvant chemotherapy regimenAdjuvant systemic therapyAdjuvant combination chemotherapyBreast cancer recurrenceYears of ageChemotherapy regimenPrognostic determinantsSystemic therapyCombination chemotherapyClinicians' estimationTumor stagePatient prognosisPatient outcomesCancer recurrenceBreast cancerMortality rateClinical practiceTumor biologyClinical settingChemotherapyBiological rationalePrognosisRecurrenceSignificant reduction
2013
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Research And Treatment 2013, 141: 421-427. PMID: 24062210, DOI: 10.1007/s10549-013-2700-1.Peer-Reviewed Original ResearchConceptsEndoxifen levelsEndocrine therapyBreast cancerCYP2D6 genotypeAdjuvant tamoxifenTamoxifen metabolismOptimal adjuvant endocrine therapyAlternative endocrine therapyBaseline whole bloodAdjuvant endocrine therapyMedical record reviewActual treatment decisionsPoor metabolizer genotypeCytochrome P450 2D6Record reviewClinical evidenceTreatment recommendationsTherapy recommendationsTreatment decisionsEstrogen receptorHormonal treatmentStage IClinical practicePatientsTamoxifenInternational guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer
Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP, Force E. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. The Breast 2013, 22: 203-210. PMID: 23601761, DOI: 10.1016/j.breast.2013.03.006.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerEarly-stage breast cancerBreast cancerTumor markersRisk/benefit ratioEuropean Breast Cancer ConferenceEarly-stage patientsEvaluation of patientsInitiation of treatmentProgression of diseaseSpecific BC subtypesTask ForceQuality of lifeType of treatmentEndocrine therapyMetastatic diseaseMetastatic involvementSystemic therapyBC subtypesPhysical examinationClinical trialsCancer ConferencePatientsClinical practiceInternational guidelines
2012
Can We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice?
Hudis CA, Citron ML, Muss H, Norton L, Winer EP. Can We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice? Journal Of Clinical Oncology 2012, 30: 3148-3149. PMID: 22851555, DOI: 10.1200/jco.2012.43.4746.Peer-Reviewed Original Research
2011
PL1-1: How To Use Endocrine Therapy for Breast Cancer: Beyond the Basics.
Winer E. PL1-1: How To Use Endocrine Therapy for Breast Cancer: Beyond the Basics. Cancer Research 2011, 71: pl1-1-pl1-1. DOI: 10.1158/0008-5472.sabcs11-pl1-1.Peer-Reviewed Original ResearchHormone receptor-positive diseaseReceptor-positive diseaseEndocrine therapyPositive diseaseBreast cancerClinical practiceExtended adjuvant therapyAdjuvant endocrine therapyBreast cancer patientsAdjuvant therapyHormonal therapyMore treatment choicesPremenopausal womenSufficient therapyLate recurrenceCancer patientsAromatase inhibitorsTreatment choiceHigh riskPatientsTherapyDrug resistanceCancer ResHormone receptorsTumorsWill preoperative trials change future clinical practice?
Lim E, Winer E. Will preoperative trials change future clinical practice? Clinical Investigation 2011, 1: 59-73. DOI: 10.4155/cli.10.3.Peer-Reviewed Original ResearchPreoperative systemic therapySystemic therapyBreast cancerOperable breast cancerManagement of patientsPST trialsPost-treatment tissuesFuture clinical practiceAdjuvant trialsBreast cancePredictive biomarkersPreoperative trialBiomarker discovery programsBiologic mechanismsClinical practiceTherapyVivo studiesTrialsOff-target effectsIdentification of pathwaysCorrelative studiesDrug developmentCancerPatientsDiscovery programs
2004
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis. Journal Of Clinical Oncology 2004, 22: 854-863. PMID: 14990641, DOI: 10.1200/jco.2004.04.158.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBreast NeoplasmsCohort StudiesCost SavingsCost-Benefit AnalysisDecision Support TechniquesDose-Response Relationship, DrugDrug Administration ScheduleDrug CostsFemaleGenes, erbB-2Genetic TestingHealth Care CostsHumansMarkov ChainsNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingQuality of LifeSurvival RateTrastuzumabTreatment OutcomeConceptsIncremental cost-effectiveness ratioMetastatic breast cancer patientsBreast cancer patientsTrastuzumab therapyCancer patientsFavourable incremental cost-effectiveness ratioTest characteristicsMetastatic breast cancerCost-effectiveness ratioEffectiveness of treatmentPositive test resultsNegative test resultsPositive resultsCost-effectiveness analysisTreatment strategiesBreast cancerHypothetical cohortTreatment candidatesHercepTest resultsPatientsClinical practiceFISH confirmationProtein overexpressionLifetime costsHercepTest
2000
Involving family members in cancer care: focus group considerations of patients and oncological providers
Speice J, Harkness J, Laneri H, Frankel R, Roter D, Kornblith A, Ahles T, Winer E, Fleishman S, Luber P, Zevon M, Mcquellon R, Trief P, Finkel J, Spira J, Greenberg D, Rowland J, Holland J. Involving family members in cancer care: focus group considerations of patients and oncological providers. Psycho-Oncology 2000, 9: 101-112. PMID: 10767748, DOI: 10.1002/(sici)1099-1611(200003/04)9:2<101::aid-pon435>3.0.co;2-d.Peer-Reviewed Original Research